Johnson & Johnson Announces Topline Results From Phase 3 MonumenTAL-6 Study Evaluating TECVAYLI + TALVEY In Adult Patients With Multiple Myeloma; Study Demonstrated Statistically Significant And Clinically Meaningful Improvements In Progression-Free Survival And Overall Survival
Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI®
Johnson & Johnson tested a new medicine combo for a serious blood cancer and found it helped patients live longer without their cancer getting worse. When a big medicine company shows their new treatment really works, people tend to feel more confident about that company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.